Muximed (Ambroxol Hydrochloride)

Ambroxol, the active ingredient in Muximed, is a mucolytic presented as a tablet for oral use. It helps loosen and clear thick bronchial secretions in patients with acute or chronic respiratory conditions.\n\nGNH India supplies Muximed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Muximed, a mucolytic, is employed in diseases of the respiratory tract where mucus viscosity is increased.\n\nAcute bronchitis: facilitates clearance of mucus, reducing cough and improving breathing.\nChronic bronchitis: helps maintain airway patency by thinning secretions.\nChronic obstructive pulmonary disease (COPD): supports mucus clearance to ease airflow limitation.\nRespiratory tract infections: assists in expelling infectious secretions and alleviating congestion.

Ambroxol is generally well tolerated, but some patients may experience adverse reactions.\n\nCommon Side Effects:\n- Nausea\n- Taste disturbance (bitter or metallic)\n- Abdominal discomfort\n- Diarrhea\n- Headache\n- Mild skin rash\n\nSerious or Rare Side Effects:\n- Allergic reactions such as urticaria or angioedema\n- Severe skin reactions (e.g., Stevens‑Johnson syndrome)\n- Hepatic dysfunction (elevated liver enzymes)\n- Eosinophilia or neutropenia\n- Anaphylactic shock\n- Unexplained fever or systemic inflammation

Before using Muximed, consider the following safety measures.\n\nAssess renal function: adjust use in severe impairment.\nMonitor for hypersensitivity: discontinue if allergic signs appear.\nUse with caution in asthma: may increase bronchial secretions.\nAvoid in patients with known hypersensitivity to ambroxol or related compounds.\nStore at ambient temperature: keep in the original pack, protect from moisture.

Ambroxol may interact with other medicines; review the following categories.\n\nMajor Interactions (Avoid):\n- Combined with other mucolytic agents: risk of excessive bronchial irritation.\n- Co‑administration with strong CYP3A4 inhibitors: may raise ambroxol plasma levels.\n\nModerate Interactions (Monitor Closely):\n- Use with antitussives containing codeine: cough suppression may mask therapeutic effect.\n- Concurrent bronchodilators: monitor for additive respiratory effects.\n- Alcohol consumption: may increase gastrointestinal irritation.